替妥木单抗 Tepezza
生产厂家：美国Horizon Therapeutics(HZNP) 地平线治疗
功能主治：治疗甲状腺眼病的新型药物，改善患者眼球突出
用法用量：用法用量 Tepezza的推荐剂量是初始剂量为10mg/kg的静脉输注，然后每三周静脉输注20mg/kg，再输注7次。
查看详情
Tepezza is an FDA-approved monoclonal antibody that works by inhibiting the actions of insulin-like growth factor-1 receptor (IGF-1R), a receptor crucial in the progression of TED. By blocking this receptor, Tepezza effectively reduces the inflammation and swelling associated with the disease, leading to a decrease in the protrusion of the eyeballs.
The clinical trials conducted on Tepezza have demonstrated its extraordinary efficacy in treating TED. In a study involving 83 patients with TED, those who received Tepezza showed significant improvements in proptosis (eyeball protrusion) compared to the placebo group. After receiving infusions of Tepezza over a period of 24 weeks, nearly 83% of patients experienced a reduction in proptosis by at least 2 mm, and 9% even achieved complete resolution of proptosis.But Tepezza's benefits go beyond just reducing proptosis. It has been found to improve other TED-related symptoms as well, including diplopia (double vision), ocular pain, eyelid swelling, and redness. Patients treated with Tepezza reported an improvement in their overall eye appearance, resulting in boosted self-esteem and quality of life.
One significant advantage of Tepezza is that it offers a long-lasting effect. Studies indicate that the improvements observed during the clinical trials were maintained for at least one year after treatment cessation. This long-lasting effect provides hope for patients with TED, as they can anticipate sustained relief from their symptoms.
In addition to effectively treating TED, Tepezza has also shown promising safety profiles. The most commonly reported side effects during clinical trials were muscle spasms, nausea, diarrhea, and fatigue, which were generally mild to moderate in severity and resolved without long-term complications. The safety data from these trials provide reassurance to both patients and healthcare providers regarding the drug's tolerability and risk-benefit analysis.
Overall, Tepezza represents a significant breakthrough in the treatment of Thyroid Eye Disease. It not only addresses the symptoms but also tackles the underlying cause, bringing hope to the millions of people suffering from this condition. This innovative drug has demonstrated remarkable efficacy, producing visible improvements in eyeball protrusion and overall eye appearance. With its long-lasting effect and favorable safety profile, Tepezza is transforming the treatment landscape of TED, significantly improving the lives of patients and offering a brighter future.
